Terns Pharmaceuticals, Inc. Common Stock (TERN)
Terns Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and liver diseases. Based in the United States, the company leverages precision medicine and advanced research techniques to create targeted treatments aimed at unmet medical needs in conditions such as non-alcoholic steatohepatitis (NASH) and related metabolic disorders.
Company News
Terns Pharmaceuticals has a promising GLP-1 weight-loss drug that could compete with treatments from Novo Nordisk and Eli Lilly. However, the company is still in early stages and faces risks, including the need for ongoing stock offerings to fund its cash-burning operations.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at $10.50 per share, as well as pre-funded warrants to purchase 2,380,952 shares. The company intends to use the net proceeds to fund research, clinical trials, and developme...
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. Take-Two reported third-quarter total net bookings of $1.34 billion, down 3% year-over-year. The company also revised its 2024 net bookings forecast to $5.25 billion and $5.3 billion, down from $5.45 billion and $...